Independent product innovation for medical devices

Find the stronger product before committing to development.

Tech Vision Engineering gives medical-device leaders an experienced external view on product concepts—studying the market, challenging assumptions, identifying meaningful improvements, and connecting the idea to testing, manufacturability and validation.

17+ yearsengineering, quality & validation
3 yearsfocused independent invention work
40+ conceptsexplored across multiple product categories
20+ ideasdeveloped through a structured process
2 US patentsowned as a pro-se inventor
The external perspective

A practical challenge to the first idea.

Development teams know their technology. I add the viewpoint of an inventor, validation engineer and product evaluator—looking across the competitive landscape and asking where the concept can become simpler, more useful, more testable and more defensible.

The goal is not to generate ideas for their own sake. It is to expose better options early, before design decisions become expensive to reverse.

01 / DISCOVER

Market & competitor scan

Map comparable products, claims, user benefits, technical approaches and visible gaps.

02 / CHALLENGE

Concept review

Test the value proposition and examine alternative mechanisms, features and workflows.

03 / DE-RISK

Engineering reality check

Connect ideas with requirements, measurement, test methods, manufacturability and validation.

Low-risk first engagement

Product Opportunity & Risk Review

A focused, fixed-scope assessment of one product concept, existing product or development direction. Designed to help CEOs and development leaders identify competitive opportunities, expose technical risks and make a better-informed investment decision before committing significant resources.

Clear boundaries · Decision-focused deliverables · Independent engineering perspective

Request a scoping call
01
Market, competitor & patent landscape
Relevant products, user benefits, technical approaches, visible market gaps and an initial screening of published patents.
02
Concept & differentiation review
Assessment of the proposed value, alternative mechanisms and prioritized opportunities for meaningful product improvement.
03
Technical & development risk review
Early risks related to functionality, testing, metrology, materials, manufacturability, validation and system integration.
04
Management recommendation
A concise executive report and presentation concluding with: Proceed, Modify, Investigate Further or Stop.
When to use this review

Bring evidence into the decision—before commitment becomes expensive.

The scope and schedule are agreed after an initial discussion and matched to the product, development stage and information available.

Before selecting a new product concept
Before detailed design and prototyping
When a concept needs stronger differentiation
When the team wants an independent challenge
Before tooling, testing or patent investment
When management needs a structured go/no-go view
ProceedThe opportunity is sufficiently differentiated and technically credible to advance.
ModifyContinue after addressing identified weaknesses or reframing the concept.
Investigate furtherCritical evidence is still missing and targeted research or testing is required.
StopThe expected risk or disadvantage does not justify further investment.

Patent scope: Patent research is provided as technical landscape screening and does not constitute a legal freedom-to-operate opinion.

Decision economics

The cost of finding out late

The later a fundamental product weakness is discovered, the more activities may need to be repeated. The figures below illustrate potential cost exposure—not guaranteed savings or industry benchmarks.

Stage of discoveryWhat an earlier review may help avoidIllustrative cost exposure
Before concept selectionMonths spent researching a weak direction, unnecessary CAD, patent work and internal engineering time.Tens to hundreds of thousands of euros
During developmentRedesign, additional prototypes, material changes, supplier rework and repeated engineering reviews.€50,000–€500,000+
After tooling and Design VerificationTool modifications, repeated testing, documentation updates, revalidation and delayed market entry.€150,000–€1.5 million+
After market launchField action, recall, lost sales, regulatory remediation, litigation and reputational damage.Millions—or substantially more

Illustrative exposure only. Actual costs depend on device complexity, development stage, regulatory classification, production scale and the nature of the issue. An independent review cannot guarantee that every risk will be identified or prevented.

The objective is not to promise a specific saving. It is to make a relatively small, focused investment before the company makes a much larger and harder-to-reverse commitment.
Selected relevant work

Experience where ideas meet evidence.

Drug delivery · NPI

Kaleido insulin pump

Supported development and introduction of a new pump version through drawing review, manufacturing and measurement-equipment validation, test-method validation, supplier collaboration and risk-based quality controls.

Autoinjectors · Design verification

Better test execution

Validated design-verification test methods using ZwickRoell testXpert and proposed a simpler, more efficient fixture concept for holding autoinjectors.

Independent invention

Concept to licensing outreach

Developed product ideas through market research, evaluation, prototypes, 3D-printed parts, IP protection, marketing materials and company outreach—funded and managed independently.

Medical manufacturing

Metrology for product introduction

Created measurement strategies, selected equipment and fixtures, supported design reviews, suppliers and NPI readiness across drug-delivery and precision-manufacturing environments.

Laboratory strategy

Technology selection

Led laboratory investments, compared measurement technologies and expanded a lab supporting a 3,000-employee manufacturing plant.

Qualification · Compliance

From requirements to evidence

Defined and executed URS/IQ/OQ/PQ, MSA/Gage R&R and test-method validation under ISO 13485 and regulated manufacturing expectations.

Technical case study · Drug delivery

A valuable product decision: stopping the “dry-needle PFS” concept early.

Could a standard glass prefilled syringe keep its staked needle dry during storage by adding a small internal stopper-valve—without changing the glass barrel, needle-staking process or autoinjector interface?

Decision reachedNO-GO in its original form
Technically conceivable, but not a competitive system-level solution under the constraints.
Simplified engineering diagram—not a production design.Blue: drug · orange: isolation/septum · dark line: needle
01 · NEEDPrevent drug–needle contact, clogging or interaction during storage.
02 · CONSTRAINTSKeep standard barrel geometry, staked needle and autoinjector interface.
03 · PRIOR ARTSearch patents for membranes, bypasses, deforming valves and plug–stopper mechanisms.
04 · MARKETCompare how current dry-needle platforms solve the same user need.
05 · KILL TESTChallenge shelf-life reliability, CCI, force, particles, drug contact and fill-finish.

Patent evidence: the mechanism already existed

BD patent EP0588148B1 describes a syringe with a sliding isolation stopper and rigid plug. Pressure moves both parts to the distal end; the stopper then moves relative to the plug, opening channels toward the needle.

  • Standard, substantially uniform barrel was part of the objective.
  • The design avoided a rupturable membrane and aimed for predictable opening force.
  • It confirmed feasibility—but also exposed the extra moving, sealing and assembly elements.

Commercial benchmark: solve it outside the PFS

Gerresheimer Gx Inbeneo® keeps the needle separated from the primary container until use. A double-ended needle pierces the cartridge septum during activation.

  • Dry needle during storage and no drug contact with the needle.
  • ISO 1.5 or 3 mL glass cartridge—not a conventional staked-needle PFS.
  • The market solution accepts an architecture change to gain a robust fluid-path boundary.

Valve routes screened

  • Pressure-ruptured or needle-pierced membrane: debris and blockage concern.
  • Enlarged barrel / bypass geometry: disrupts standard glass manufacturing.
  • Deforming pressure valve: uncertain opening and continued force demand.
  • Sliding stopper + plug: more predictable, but adds contact materials, assembly and moving interfaces.

The system question that changed the decision

The initial question was “Can a valve be designed?” The decisive question became: “Can it remain sterile, compatible and predictably open after the full shelf life—while adding no unacceptable fill-finish, dose, force or manufacturing penalty?” Under the original constraints, the answer was not convincingly yes.

What technically killed the original direction

One small part created a new primary-container system.

×Additional fill-finish insertion and inspection operation.
×New container-closure-integrity and 24–36 month shelf-life evidence.
×Elastomer, extractables/leachables and particle exposure in the drug path.
×Dead volume, trapped air and potential dose loss near the syringe cone.
×Break-open force competing with the autoinjector’s available force budget.
×Siliconization, glide and tolerances affecting repeatable valve activation.
AI-AUGMENTED

AI accelerated the search; engineering judgement made the decision. AI was used to widen patent and competitor discovery, connect mechanisms across sources and test counterarguments quickly. The final no-go came from structured engineering review: requirements, physical mechanism, shelf-life risks, manufacturing fit and commercial differentiation.

Public-source references: EP0588148B1 — Syringe having needle isolation features · Gerresheimer/Midas Pharma — Gx Inbeneo functional testing. This case study is a retrospective concept-screening example, not a claim of product development for either company.

A repeatable invention discipline

Not a brainstorm. A complete path from market to outreach.

Years of applying a structured licensing method changed how I evaluate product opportunities: start with the market, develop for a real need, prove the concept clearly, protect what matters, and communicate the benefit.

01Study the market
02Invent for the market
03Evaluate ideas
04Prototype
05Define the benefit
06Create sell materials
07Protect the idea
08Reach companies
InventRight One-on-One Coaching Program guidebook used during independent invention work

Applied learning through the InventRight coaching framework. Tech Vision Engineering is not presented as affiliated with or endorsed by InventRight.

Cristian Istrate, founder of Tech Vision Engineering
Cristian Istrate

Inventor’s curiosity. Validation engineer’s discipline.

Founder of Tech Vision Engineering. Mechanical engineer and EU-based independent consultant, supporting medical-device and regulated-manufacturing teams through remote collaboration and on-site projects across Europe.

Product DevelopmentDesign V&VDrug DeliveryTMVMetrology & MSAIQ/OQ/PQNPI QualityISO 13485

Experience includes ViCentra, Haselmeier, Phillips-Medisize, Bespak Medical, Continental and Siemens environments.

Bridge between functionsR&D, Quality, Validation, Manufacturing, suppliers and test laboratories.
Hands-on product judgementDrawings, prototypes, fixtures, measurement strategies, testing and production readiness.
Commercial understandingBenefit statements, selling materials, intellectual-property awareness and company outreach.
Regulated evidenceRequirements, risk controls, protocols, statistical analysis and defensible documentation.
For CEOs & development leaders

Before you lock the concept, invite one more experienced perspective.

Share the product area, development stage and decision you are facing. We can define a focused review with clear boundaries, deliverables and a fixed fee.

Available for focused European projects, remote collaboration and on-site engagements.

Contact Cristian Istrate →